Pfizer (PFE) Payables (2009 - 2026)

Pfizer has disclosed Payables across 18 years of filings, most recently posting $4.5 billion for Q1 2026.

• In Q1 2026, Payables fell 14.01% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (down 14.01% YoY), while the FY2025 annual figure was $7.7 billion, down 4.77% from the prior year.
• Payables fell to $4.5 billion in Q1 2026, from $7.7 billion in the prior quarter.
• Over the last five years, Payables for PFE reached as high as $9.1 billion in Q4 2022 and fell as low as $4.5 billion in Q1 2026.
• The 5-year median for Payables is $7.5 billion (2024), against an average of $6.9 billion.
• Annual changes were most pronounced in 2022 — Payables jumped 35.48% — and 2023, when it sank 37.29%.
• A 5-year view of Payables shows it stood at $9.1 billion in 2022, then fell by 0.33% to $9.1 billion in 2023, then declined by 11.14% to $8.1 billion in 2024, then fell by 4.77% to $7.7 billion in 2025, then sank by 41.37% to $4.5 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.5 billion, $7.7 billion, and $5.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.